

MOL #19133

**Dexas1 Negatively Regulates Protein Kinase C δ :
Implications for Adenylyl Cyclase 2 Signaling**

Chau H. Nguyen and Val J. Watts

Department of Medicinal Chemistry and Molecular Pharmacology

Purdue University

West Lafayette, IN 47907, USA

MOL #19133

Running Title: Dexras1 Inhibits PKC δ

Corresponding author: Val J. Watts

Department of Medicinal Chemistry & Molecular Pharmacology

Purdue University

575 Stadium Mall Dr., RHPH 210

West Lafayette, IN 47907, USA

Tel: (765) 496-3872

Fax: (765) 494-1414

email: wattsv@pharmacy.purdue.edu

Text Statistics:

Text pages:	35	Words in Abstract:	243
Tables:	0	Words in Introduction:	516
Figures:	10	Words in Discussion:	1293
References:	35		

Abbreviations: AC (1-9), adenylyl cyclase type 1-9; AGS1, activator of G protein signaling 1; Dexras1, dexamethasone-induced Ras protein 1; ERK 1/2, extracellular-signal regulated kinase; GEF, guanine nucleotide exchange factor; GIRK, G $\beta\gamma$ -regulated inwardly rectifying potassium channel; GPCR, G protein coupled receptor; HEK, human embryonic kidney; PDK1, phosphoinositide-dependent kinase 1; PMA, phorbol 12-myristate 13-acetate

MOL #19133

Abstract

We have identified Dexas1 as a negative regulator of protein kinase C (PKC) δ and the consequences of this regulation have been examined for adenylyl cyclase (EC 4.6.1.1) type 2 (AC2) signaling. Dexas1 expression in HEK293 cells completely abolished dopamine D₂ receptor-mediated potentiation of AC2 activity, which is consistent with previous reports of its ability to block receptor-mediated G $\beta\gamma$ signaling pathways. Additionally, Dexas1 significantly reduced PMA-stimulated AC2 activity but did not alter G α_s -mediated cyclic AMP accumulation. Dexas1 appeared to inhibit PMA stimulation of AC2 by interfering with PKC δ autophosphorylation. This effect was selective for the δ isoform, as Dexas1 did not alter autophosphorylation of PKC α or PKC ϵ . Dexas1 disruption of PKC δ autophosphorylation resulted in a significant blockade of PKC kinase activity as measured by [³²P] γ -ATP incorporation using a PKC-specific substrate. Moreover, Dexas1 and PKC δ co-immunoprecipitated from whole cell lysates. Dexas1 did not alter the membrane translocation of PKC δ ; however, the ability of Dexas1 to interfere with PKC δ autophosphorylation was isoprenylation-dependent as determined using the farnesyltransferase inhibitor, FTI-277, and a CAAX box-deficient Dexas1 (C277S) mutant. PMA-stimulated AC2 activity was also not affected by Dexas1C277S. Collectively, these data suggest that Dexas1 functionally interacts with PKC δ at the cellular membrane through an isoprenylation-dependent mechanism to negatively regulate PKC δ activity. Moreover our study suggests that Dexas1 acts to modulate the activation of AC2 in an indirect fashion by inhibiting both G $\beta\gamma$ - and PKC-stimulated AC2 activity. The current study provides a novel role for Dexas1 in signal transduction.

MOL #19133

Dexas1/AGS1/RASD1 was originally identified as a dexamethasone-inducible member of the Ras superfamily of monomeric G proteins (Kemppainen and Behrend, 1998). Dexas1 possesses the consensus guanine nucleotide-binding motif identified in Ras proteins, as well as a membrane-targeting CAAX box at its carboxy terminus (Cismowski et al., 2000). It has been proposed that Dexas1 may function as a guanine nucleotide exchange factor (GEF) for $G\alpha_{i/o}$ proteins, and consequently, compete with G protein coupled receptors (GPCR) to disrupt receptor-G protein signaling (Graham et al., 2002; Graham et al., 2004; Takesono et al., 2002). Although Dexas1 has been shown to possess GEF activity for $G\alpha_{i/o}$ subunits *in vitro* (Cismowski et al., 2000), direct data supporting its role as a GEF *in vivo* is still lacking. In mammalian cells, Dexas1 blocks agonist-stimulated $G_{i/o}$ -coupled receptor activation of extracellular signal-regulated kinase (ERK 1/2) (Graham et al., 2002; Nguyen and Watts, 2005) and $G\beta\gamma$ -regulated inwardly rectifying potassium channels (Takesono et al., 2002). Dexas1 also inhibits $G\beta\gamma$ -dependent heterologous sensitization of adenylyl cyclase type 1 (AC1), without interfering with the acute inhibition of AC1 activity by $G\alpha_{i/o}$ subunits (Nguyen and Watts, 2005). In human cancer cell lines, Dexas1 suppresses clonogenic growth through a pertussis toxin-insensitive pathway, although the exact mechanism for this effect is unknown (Vaidyanathan et al., 2004). The contrasting observation that Dexas1 interferes with receptor-mediated $G\beta\gamma$ signaling pathways, without altering receptor-stimulated $G\alpha_{i/o}$ signaling, and that Dexas1 can also regulate aberrant cellular growth in a pertussis toxin-insensitive manner suggests the possibility of a more complex role for Dexas1 in signal transduction than previously hypothesized.

Adenylyl cyclase 2 belongs to the $G\beta\gamma$ -stimulated subfamily of adenylyl cyclase isoforms (for review, see Hanoune and Defer, 2001). Adenylyl cyclase 2 signaling can be promoted by

MOL #19133

activators of protein kinase C (PKC) such as diacylglycerol or phorbol esters (Bol et al., 1997; Jacobowitz and Iyengar, 1994). Protein kinase C is a family of serine/threonine kinases comprised of at least 12 members that are categorized into three groups based on their regulatory properties: conventional PKCs (cPKC; α , β , and γ), novel PKCs (nPKC; ϵ , η , δ , θ), and atypical PKCs (aPKC; λ , ζ) (for review, see Newton, 2001). The protein kinase C isoform(s) responsible for phosphorylating AC2 has not been identified, although convention suggests it is a member of the cPKC or nPKC subfamily because aPKCs are insensitive to diacylglycerol stimulation. The ability of Dexras1 to inhibit $G_{i/o}$ -coupled receptor-stimulated $G\beta\gamma$ signaling pathways suggests that Dexras1 may interfere with the conditional activation of AC2 by $G\beta\gamma$ dimers (Graham et al., 2002; Nguyen and Watts, 2005; Takesono et al., 2002).

In this report we reveal that Dexras1 abolishes dopamine D_{2L} receptor-mediated potentiation of AC2 activity, presumably by interfering with agonist-stimulated $G\beta\gamma$ signaling. More significantly, we demonstrate that Dexras1 inhibits phorbol ester stimulation of AC2, thereby implicating a role for Dexras1 in PKC-dependent signaling pathways. To provide insight into the mechanisms for this blockade, we have employed a series of biochemical, pharmacological, and genetic approaches to demonstrate that Dexras1 inhibits PKC δ activity. Collectively, our data reveal that Dexras1 negatively modulates AC2 signaling in an indirect fashion by inhibiting both $G\beta\gamma$ - and PKC-stimulated AC2 activity.

MATERIALS & METHODS

Materials – [³H]Cyclic AMP was purchased from PerkinElmer Life Science Products (Boston, MA). Fetalclone1 serum and bovine calf serum were purchased from Hyclone (Logan, UT). Rabbit Dexas1 antibody was purchased from Calbiochem (San Diego, CA). Isoform-specific phospho-PKC antibodies (PKC α : Thr638, PKC δ : Ser643, PKC ϵ : Thr710) were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Anti-PKC δ and anti-PKC ϵ antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-FLAG antibody, isoproterenol, phorbol 12-myristate 13-acetate (PMA), quinpirole, isobutylmethylxanthine, and most other reagents were purchased from Sigma-Aldrich (St. Louis, MO). The cDNA for Dexas1 was obtained from Guthrie cDNA Resource Center (<http://www.cdna.org>).

Cell Culture – HEK293T cells stably expressing the rat dopamine D_{2L} receptor was generated as described previously (Neve et al., 2001). HEK-AC2 cells were generated by transfection using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) and selection using G418 (900 μ g/ml). G418-resistant colonies were screened and selected based on the response to PMA stimulation. Cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with 5 % fetalclone1 serum, 5 % bovine calf serum, 0.05 U/ml penicillin, and 50 mg/ml streptomycin. Cells were grown in a humidified incubator in the presence of 5 % CO₂ at 37°C.

Transfections – At 90-95 % confluency, transient transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. For experiments examining AC2 activity in the presence of only wild-type Dexas1 (Figure 1), co-transfections were performed using the dual expression vector, pBudCE4 (Invitrogen), containing AC2 alone or in combination with Dexas1. All other co-transfections

MOL #19133

were performed using separate plasmids encoding individual cDNAs and transfections were equalized by mass using pcDNA3.

Cyclic AMP Accumulation Assay – Cells were seeded in 24-well cluster plates at a concentration of approximately 150 000 cells/well and transfections were performed as described above. At 48 hours post-transfection, cells were washed with Earle's balanced salt solution (EBSS) assay buffer (EBSS containing 2 % bovine calf serum, 0.025 % ascorbic acid, and 15 mM Na⁺-HEPES) for 5 min at room temperature. The medium was decanted and the cells were placed on ice. All stimulations were performed in the presence of 500 μM IBMX at 37°C for 15 min. The stimulation media was decanted and the reaction was terminated by the addition of 100-200 μl of 3 % ice-cold trichloroacetic acid. The plates were stored at 4°C overnight before quantification of cyclic AMP using a competitive binding assay adapted from Watts and Neve (Watts and Neve, 1996).

Immunodetection – Cells were seeded in 6-well cluster plates at a concentration of approximately 750 000 cells/well and transfections were performed as described above. At 48 hours post-transfection (72 hr if cells were serum-starved overnight), the plates were placed on ice and lysed with ice-cold lysis buffer (1 mM HEPES, pH 7.4, 2 mM EDTA, 1 mM DTT, 0.3 mM PMSF, 20 μg/ml aprotinin, 1 μg/ml leupeptin, plus 1 % NP-40) for 10 min. The cells were then scraped from the plates, centrifuged at 13 000 x g for 10 min, and the supernatant was retained for analysis. For subcellular fractionation experiments, cells were lysed with ice-cold lysis buffer (without NP-40) and centrifuged at 100 000 x g for 30 minutes at 4°C to generate the pellet (membrane) and supernatant (cytosol) fractions. Membrane pellets were then solubilized in ice-cold lysis buffer containing 1 % NP-40. Total protein content was determined using a BCA protein assay kit (Pierce Biotechnology, Inc., Rockford, IL). Protein samples were

MOL #19133

equalized by dilution and resolved by SDS-polyacrylamide gel electrophoresis and electro-transferred to Bio-Rad polyvinylidene difluoride (PVDF) membranes (Hercules, CA). Nonspecific antibody binding was blocked by incubating membranes overnight in 5 % non fat dried milk at 4°C. Membranes were washed with Tris-buffered saline and incubated with the indicated primary antibody for 3 hr. The membranes were washed and immunodetection was accomplished using the Amersham Life Sciences enhanced chemifluorescence (ECF) western blotting kit (Buckinghamshire, UK) according to the manufacturer's protocol. Following final antibody incubation, membranes were again washed, exposed to ECF substrate, and then scanned using the Molecular Dynamics Storm Imaging System (Sunnyvale, CA). Immunoblots were quantified using ImageQuant software according to manufacturer instructions. Where indicated the amount of PKC δ autophosphorylation was normalized as the ratio of phospho-PKC δ to total PKC δ expression (phospho-PKC δ /total PKC δ).

Co-immunoprecipitation – Cells in 150 mm tissue culture plates were washed with PBS and then incubated with Dithiobis[succinimidylpropionate] (25 mM) at room temperature for 30 min. The reaction was terminated by addition of 20 mM Tris-HCl (pH 7.5) for 15 minutes. The cells were then collected in PBS by centrifuging at 200 x *g* for 10 min and washed twice with PBS. Cells were then incubated with lysis buffer (PBS, 5 mM EDTA, 0.5 % Triton-X 100, 0.1 mM PMSF, 10 μ M leupeptin, and 25 μ g/ml aprotinin) at 4°C for 30 min on a rotating platform. The lysate was cleared by centrifuging at 13 000 x *g* for 30 min at 4°C. The supernatant was incubated with Protein G sepharose beads in the absence of antibody for 1 hr at 4°C to remove nonspecifically bound proteins. The supernatant was cleared by centrifugation and transferred to a new tube containing Protein G sepharose beads and 5 μ g primary antibody at 4°C overnight.

MOL #19133

The beads were pelleted and washed 5 times with PBS for 2 minutes, and then resuspended in 2x laemmli sample buffer for immunoblot analysis as described above.

In vitro PKC Kinase Assay – PKC activity was measured with the Promega SignaTECT PKC assay kit according to the manufacturer's protocol with minor modifications to directly examine PKC δ activity. Briefly, PKC was enriched from cell lysates with DEAE ion exchange chromatography. The eluate was used to measure [32 P] γ -ATP incorporation into the PKC-specific substrate, neurogranin, under control and PKC-stimulated conditions. The PKC stimulation buffer contained (final concentration): 0.25 mM EGTA, 0.1 mg/ml BSA, 0.3 mg/ml phosphatidylserine, 0.03 mg/ml diacylglycerol, 20 mM Tris-HCl (pH 7.5), 10 mM MgCl $_2$, 100 nM PMA, 100 μ M biotinylated neurogranin peptide substrate, 100 μ M ATP, and 0.5 μ Ci [32 P] γ -ATP (3000Ci/mM). The control buffer was essentially identical to the stimulation buffer but did not contain phosphatidylserine, diacylglycerol, or PMA. All reactions were performed in the absence of Ca $^{2+}$ to selectively activate nPKC isoforms. The reaction was incubated in a 30°C water bath for 5 min and terminated by the addition of 7.5 M guanidine hydrochloride. An equal amount of reaction mix was spotted onto a streptavidin-coated membrane (Promega SAM 2 biotin capture membrane), washed three times each with 2 M NaCl, 2 M NaCl with 1 % H $_3$ PO $_4$, and once with dH $_2$ O. The membrane was dried and counted in a Beckman LS6500 scintillation counter. Total protein content from the DEAE eluate was determined using a BCA protein assay kit.

Data & Statistical Analysis – Statistical analyses were performed using GraphPad Prism and GraphPad InStat software (GraphPad Software Inc., San Diego, CA). A *p* value of < 0.05 defined significance.

RESULTS

Dexas1 Inhibits G $\beta\gamma$ - and PMA-stimulated AC2 Activity

AC2 is conditionally activated by G $\beta\gamma$ subunits upon acute activation of the G $_{i/o}$ -coupled dopamine D $_{2L}$ receptor (Watts and Neve, 1997). Since Dexas1 has been shown to block receptor-mediated G $\beta\gamma$ -dependent signaling pathways, we investigated the effects of Dexas1 on dopamine D $_{2L}$ receptor-mediated potentiation of AC2 activity. The activity of AC2 was examined by stimulating cells with isoproterenol to activate endogenous G α_s -coupled β -adrenergic receptors. Isoproterenol-stimulated cyclic AMP accumulation was significantly increased above basal levels in AC2 transfected cells (Figure 1a). The G α_s -mediated activation of AC2 was retained in Dexas1 transfected cells, as cyclic AMP accumulation values were comparable to those observed in the absence of Dexas1 (Figure 1a). In agreement with its acute regulatory properties, co-stimulation of cells with isoproterenol and the D $_2$ receptor agonist, quinpirole, resulted in greater than 50 % potentiation of AC2 activity (Figure 1a). This effect was completely abolished in cells co-transfected with Dexas1, which is consistent with the ability of Dexas1 to block receptor-mediated activation of G $\beta\gamma$ signaling effectors (Figure 1a).

We examined further the role for Dexas1 in regulating AC2 activity by stimulating cells with the AC2 activator, PMA. Cells transfected with only AC2 exhibited robust cyclic AMP accumulation in response to stimulation with PMA when compared to basal cyclic AMP levels (Figure 1b). Similar to the results obtained from G α_s stimulation, cyclic AMP accumulation was potentiated greater than 50 % following co-stimulation with PMA and quinpirole in comparison to the response from PMA stimulation alone (Figure 1b). Surprisingly, Dexas1 co-transfection significantly reduced PMA-stimulated cyclic AMP accumulation approximately 80 % (Figure 1b). The ability of D $_{2L}$ receptor activation to potentiate AC2-mediated cyclic AMP

MOL #19133

accumulation was abolished in Dexas1 co-transfected cells (Figure 1b). These results suggest that Dexas1 inhibits PKC-mediated activation of AC2 and is the first evidence that Dexas1 may act to obstruct PKC-dependent signaling pathways.

PMA-stimulated AC2 activity is PKC δ dependent

As a first step in identifying the mechanisms by which Dexas1 may be inhibiting PMA stimulation of AC2, we used pharmacological inhibitors of PKC to provide insight into the PKC isoform(s) that may be activating AC2. We employed two PKC inhibitors with selectivity for phorbol ester-sensitive PKC isoforms: bisindolylmaleimide is a broad range PKC inhibitor that targets many members of cPKC and nPKC isoforms, whereas rottlerin has greater specificity for PKC δ (Gschwendt et al., 1994). HEK-AC2 cells were examined for PMA-stimulated cyclic AMP accumulation in the absence and presence of bisindolylmaleimide or rottlerin. PMA stimulation of AC2 resulted in greater than 6-fold increase in cyclic AMP accumulation above basal (Figure 2a). The PKC inhibitors bisindolylmaleimide and rottlerin significantly reduced the PMA-stimulated cyclic AMP response to approximately 2-fold above basal (Figure 2a). In contrast, neither PKC inhibitor had any effect on PKC-independent activation of AC2 by G α_s (Figure 2a). Isoproterenol-stimulated cyclic AMP accumulation remained at greater than 6-fold above basal in the presence of both inhibitors (Figure 2a). These data suggest that PKC δ activity is necessary for phorbol ester stimulation of AC2.

In a second approach to investigate the role of PKC δ in phorbol ester activation of AC2, we performed the converse experiment to determine whether expression of recombinant PKC δ was sufficient to enhance PMA-stimulated AC2 activity. Cells were transiently transfected with AC2 in the absence and presence of PKC δ and PMA-stimulated AC2 activity was examined. Cells transfected with only AC2 exhibited a significant increase in cyclic AMP accumulation

MOL #19133

following stimulation with PMA (Figure 2b). Likewise, when cells were co-transfected with AC2 and PKC δ , a robust increase in PMA-stimulated cyclic AMP accumulation was also observed; however, the magnitude of cyclic AMP accumulation in response to PMA stimulation in the presence of recombinant PKC δ was more than double that from cells transfected with AC2 alone (Figure 2b). These data confirm that stimulation of PKC δ is sufficient to activate AC2. Collectively, these data suggest that PKC δ plays a prominent role in phorbol ester stimulation of AC2.

Dexas1 Interferes with PKC δ Autophosphorylation

The results from our pharmacological experiments prompted us to investigate the effects of Dexas1 on PKC δ autophosphorylation, as autophosphorylation has been identified as a crucial component in regulating PKC catalytic activity (Newton, 2001). Transfection of PKC δ into cells resulted in robust immunoreactivity of phospho-serine 643 (Figure 3a). However, when cells were co-transfected with PKC δ and Dexas1, PKC δ autophosphorylation was reduced (Figure 3a). Because a decrease in PKC δ expression levels would decrease PKC δ autophosphorylation levels, the effect of Dexas1 transfection on the expression levels of total PKC δ were also explored. Immunoblot analysis revealed that the levels of endogenous PKC δ in the presence of transfected Dexas1 were 98 ± 11 % (n=4) when compared to vector transfected control cells (Figure 3a, lanes 1 & 2). Likewise, when cells were co-transfected with PKC δ and Dexas1, the expression of total PKC δ (endogenous and recombinant) was 100 ± 4 % of that from control cells that were transfected with PKC δ alone (Figure 3a, lanes 3 & 4). These data provide evidence that Dexas1 interferes with PKC δ autophosphorylation and not PKC δ expression. The effect of Dexas1 on PKC δ autophosphorylation was further analyzed by

MOL #19133

normalizing the amount of PKC δ autophosphorylation as a ratio of total PKC δ expression (phospho-PKC δ /total PKC δ) for each transfection condition. This analysis was designed to control directly for any effects that total PKC δ expression may have on PKC δ autophosphorylation. The analyses of the normalized data revealed that transfection of Dexas1 reduced PKC δ autophosphorylation by $27 \pm 2\%$ when compared to cells transfected with PKC δ alone (Figure 3b). The results of this analysis support our initial immunoblot studies and provide stronger evidence that the effects of Dexas1 on PKC δ autophosphorylation are independent of Dexas1-induced changes in PKC δ expression.

The specificity of Dexas1 to interfere with PKC δ autophosphorylation was examined by evaluating its effects on other PKC isoforms. Cells were transiently transfected with either the conventional PKC α or the novel PKC ϵ in the absence and presence of Dexas1. Autophosphorylation of PKC α and PKC ϵ was very robust in cells transfected with the respective cDNA (Figure 3). Co-transfection of Dexas1 did not alter the autophosphorylation of PKC α (Figure 3c) or PKC ϵ (Figure 3d). Accordingly, total protein expression of each PKC isoform was not altered when co-transfected with Dexas1 (data not shown). Dexas1 was robustly co-expressed with PKC α and PKC ϵ , indicating that the lack of an effect on the autophosphorylation of these two PKC isoforms was not due to impaired Dexas1 expression (Figure 3). These data reveal that Dexas1 acts to interfere with the autophosphorylation of the novel PKC family member, PKC δ , in an isoform-specific manner.

Dexas1 Inhibits PKC Enzymatic Activity

PKC δ autophosphorylation at serine 643 has been identified to be a key event in regulating its kinase activity (Li et al., 1997). Therefore, we investigated if the ability of Dexas1 to disrupt autophosphorylation at this residue translated into an ability to inhibit its

MOL #19133

enzymatic activity. Cells were transiently transfected with PKC δ in the absence and presence of Dexas1. DEAE sepharose ion exchange chromatography was used to enrich PKC δ before performing an *in vitro* kinase assay designed to examine nPKC enzymatic activity using neurogranin as a PKC-specific substrate. Transfection of PKC δ resulted in greater than 300 % increase in PKC specific enzymatic activity above that of endogenous nPKC isoforms (Figure 4). Co-transfection of Dexas1 reduced PKC kinase activity by approximately 50 % (Figure 4). Immunoblot analysis of eluates following DEAE chromatography revealed that total PKC δ levels were comparable, whereas there was reduced levels of autophosphorylated PKC δ in eluates from Dexas1-transfected cells (Figure 4, inset). These data provide evidence that Dexas1 inhibits PKC kinase activity.

Dexas1 Interacts with PKC δ in Intact Cells

We next explored the possibility that Dexas1 may be physically interacting with PKC δ to disrupt its autophosphorylation and enzymatic activity. We, therefore, examined the ability of Dexas1 to co-immunoprecipitate with PKC δ . Cells were co-transfected with PKC δ and either Dexas1 or vector control. Cell lysates were then subjected to immunoprecipitation with anti-PKC δ antibody and the immunoprecipitates were examined for the presence of Dexas1 by immunoblot analysis. The blot revealed an approximately 31 kDa band immunoreactive to anti-Dexas1 antibody following PKC δ immunoprecipitation (Figure 5). The band was more reactive from cells transfected with Dexas1 cDNA compared to that of vector transfected control cells, although Dexas1 immunoreactivity was also observed in the absence of transfected Dexas1 (Figure 5). These data suggest that PKC δ can physically associate with endogenous and recombinant Dexas1 in intact cellular systems. Moreover, the combined data implicate this interaction as a mechanism to negatively regulate PKC δ signaling.

Dexas1 Does Not Inhibit PKC δ Membrane Translocation

Although Dexas1 possesses a membrane-targeting CAAX motif, there have been conflicting reports as to its localization within the cell (Cismowski et al., 2000; Fang et al., 2000). Furthermore, studies have suggested that not all of Dexas1 effects are isoprenylation-dependent (Graham et al., 2001). One possible mechanism for the ability of Dexas1 to interact and disrupt PKC δ signaling may be that it is acting in the cytosol to interfere with membrane translocation of this kinase. We investigated this possibility by transfecting cells with PKC δ in the absence and presence of Dexas1 to examine the ability of PMA to promote membrane translocation of phospho-PKC δ . Under resting conditions, phosphorylated PKC δ was found predominantly in the cytoplasmic fractions (Figure 6, lanes 1 & 3). Stimulating cells with PMA for 30 minutes resulted in the translocation of PKC δ to the membrane fractions (Figure 6, lanes 2 & 4). Although Dexas1 expression decreased the autophosphorylation of PKC δ , the PMA-induced membrane translocation of PKC δ was retained in cells co-transfected with Dexas1 (Figure 6, lanes 3 & 4). These data suggest that Dexas1 does not interfere with the membrane translocation of PKC δ to inhibit PMA-stimulated AC2 activity.

Dexas1 Regulation of PKC δ Autophosphorylation is Isoprenylation-dependent

Since Dexas1 did not appear to interfere with cytosolic PKC δ to inhibit its membrane translocation, we continued our efforts by investigating the requirement for Dexas1 to be membrane-localized to regulate PKC δ . Our initial experiments used a pharmacological approach to examine the isoprenylation-dependent regulation of PKC δ by Dexas1. Previous studies have determined that H-Ras is a target for farnesylation at its CAAX box; therefore, we employed the farnesyl transferase inhibitor, FTI-277, based on the high sequence homology between the CAAX box of Dexas1 (CVIS) and that of H-Ras (CVLS). Consistent with our previous data,

MOL #19133

transfection of PKC δ exhibited robust autophosphorylation at serine 643 that was significantly reduced by Dexas1 (Figure 7). In contrast, treatment of cells with the peptidomimetic, FTI-277, abolished the ability of Dexas1 to negatively regulate PKC δ autophosphorylation (Figure 7b). PKC δ autophosphorylation was comparable in the absence and presence of Dexas1 when cells were treated with FTI-277 (Figure 7). The expression of PKC δ was not altered by Dexas1 or FTI-277 (data not shown). These data suggest that Dexas1 is targeted to the cellular membrane through an isoprenylation-dependent mechanism to negatively regulate PKC δ .

To provide support for our pharmacological evidence, we utilized a CAAX box-deficient Dexas1 mutant (C277S) to determine if Dexas1 must be targeted to the cellular membrane to disrupt PKC δ autophosphorylation. Initial experiments confirmed the Dexas1C277S mutant failed to localize to membrane fractions (Figure 8). In contrast, wild-type Dexas1 was abundantly expressed in both the cytosolic and membrane fractions (Figure 8). These data demonstrate that in the absence of an intact CAAX box, Dexas1 fails to localize to the cellular membrane. Our subsequent experiments examined the effect of Dexas1C277S on PKC δ autophosphorylation. Transient transfection of PKC δ revealed robust autophosphorylation of this novel PKC isoform that was significantly decreased by co-transfecting wild-type Dexas1 (Figure 9). In contrast, co-transfection of cells with the Dexas1C277S mutant failed to alter PKC δ autophosphorylation (Figure 9). Phospho-PKC δ immunoreactivity in the presence of Dexas1C277S was comparable to that observed when cells were transfected with PKC δ alone. Immunoblot analysis confirmed the expression of wild-type and mutant Dexas1 proteins in whole cell lysates (Figure 9c).

MOL #19133

Dexas1-mediated Inhibition of AC2 Signaling is Isoprenylation-dependent

We continued our studies with Dexas1C277S and investigated its effects on PMA-stimulated AC2 activity. Cells were co-transfected with AC2 and either wild-type Dexas1 or Dexas1C277S and subsequently examined for PMA-stimulated cyclic AMP accumulation. The results of these studies parallel the effects of Dexas1 and Dexas1C277S on PKC δ autophosphorylation. Transfection of Dexas1 resulted in a significant decrease in PMA stimulation of AC2 (Figure 10), which is consistent with our earlier findings. In contrast, Dexas1C277S failed to inhibit PMA-stimulated AC2 activity; PMA-stimulated cyclic AMP accumulation was comparable in the absence and presence of Dexas1C277S (Figure 10). These data demonstrate that an intact CAAX box is also required for Dexas1-mediated inhibition of PMA-stimulated AC2 activity. Collectively, our study suggests that Dexas1 functionally interacts with PKC δ at the cellular membrane to interfere with PKC-dependent regulation of AC2 signaling.

DISCUSSION

In this report we provide evidence that Dexas1 may have a dual role in modulating the activation of AC2 signaling by concurrently blocking PKC and G $\beta\gamma$ activity – two proteins that function as activators of AC2. Dexas1 appeared to preferentially target G $\beta\gamma$ - and PKC-dependent activation of AC2, as G α_s -mediated cyclic AMP accumulation was not significantly altered. The ability of Dexas1 to block G $_{i/o}$ -coupled receptor-mediated potentiation of AC2 activity is consistent with previous reports that Dexas1 may function to negatively regulate G $\beta\gamma$ -dependent signaling pathways (Cismowski et al., 2000; Graham et al., 2002; Nguyen and Watts, 2005; Takesono et al., 2002). In contrast, the ability of Dexas1 to interfere with phorbol ester regulation of AC2 activity presents a novel role for Dexas1 in signal transduction.

We provide evidence that Dexas1 acts to negatively regulate PKC δ signaling in intact cells. Dexas1 significantly reduced PKC δ autophosphorylation at serine 643 and the functional consequence was a loss of PKC δ catalytic activity. This is in agreement with a previous study that identified serine 643 of PKC δ as an important autophosphorylation site for its enzymatic activity (Li et al., 1997). The role for Dexas1 in regulating PKC function appears to be selective for the δ isoform, as Dexas1 did not interfere with the autoregulation of PKC α or PKC ϵ . Moreover, Dexas1 regulation of PKC δ signaling was dependent on isoprenylation-mediated membrane localization, as autophosphorylation of PKC δ was neither altered by a CAAX box-deficient Dexas1 mutant, nor when cells were treated with the farnesyltransferase inhibitor, FTI-277. These results are consistent with observations that a constitutively active, but CAAX box-deficient Dexas1 mutant (A178V/C277term) failed to inhibit cAMP-stimulated hGH secretion in AtT-20 corticotroph cells in comparison to the 86 % reduction of secretion induced by Dexas1A178V alone (Graham et al., 2001). The data presented in this report support a model in

MOL #19133

which Dexras1 negatively regulates PKC δ through an isoprenylation-dependent mechanism: (1) Dexras1 appears to be post-translationally modified by farnesylation of its CAAX box and localizes to the cellular membrane. (2) At the membrane, Dexras1 functionally interacts with PKC δ and interferes with its autoregulatory mechanisms. (3) The disruption of autophosphorylation results in a decrease in PKC kinase activity. The precise mechanism by which Dexras1 disrupts PKC δ autophosphorylation (step 2 above) is unclear at this time. Whether Dexras1 blocks PKC δ -mediated autophosphorylation at serine 643 or if Dexras1 acts to promote the activity of a phosphatase has yet to be determined. It should be noted that Dexras1 regulation of PKC δ autophosphorylation does not appear to be the sole factor involved in its ability to inhibit phorbol ester-stimulated AC2 activity. The moderate effect of Dexras1 on PKC δ autoregulation is more likely to be a contributing factor towards its larger effects on AC2 activity. As Dexras1 can also regulate G $\beta\gamma$ signaling (Graham et al., 2002; Nguyen and Watts, 2005; Takesono et al., 2002), it may be that Dexras1 interferes with multiple inputs to AC2 that function in an additive or synergistic manner for maximal AC2 activity. Dexras1 may also be involved in other aspects of adenylyl cyclase signaling that have yet to be characterized.

Dexras1 has been proposed to function as a GEF for G $\alpha_{i/o}$ proteins (Cismowski et al., 2000), although there is evidence to suggest that Dexras1 may also regulate pertussis toxin-insensitive pathway (Vaidyanathan et al., 2004). In combination with the results of this study, one interpretation for these data may be that Dexras1 can also regulate G $_{i/o}$ protein signaling through an indirect pathway that involves PKC. For example, the ability of Dexras1 to inhibit receptor-stimulated activation of ERK 1/2 (Graham et al., 2002) and heterologous sensitization of AC1 (Nguyen and Watts, 2005) may be partly attributed to the block of PKC activity. Many G $_{i/o}$ -coupled receptors have been reported to transactivate MAP kinases through a complex

MOL #19133

signaling pathway that involves $G\beta\gamma$ regulation of PKC (Wetzker and Bohmer, 2003). Similarly, pertussis toxin-sensitive sensitization of AC isoforms has also been proposed to occur via an intricate $G\beta\gamma$ - and PKC-dependent pathway (Nguyen and Watts, 2005; Thomas and Hoffman, 1996; Varga et al., 2003). Therefore, inhibition of PKC δ activity may contribute towards the selective blockade of agonist-stimulated $G\beta\gamma$ -dependent signaling pathways by Dexras1. Thus, the model for Dexras1 in GPCR signal transduction might be amended to include an indirect regulation of pertussis toxin-sensitive $G_{i/o}$ protein signaling through a PKC δ -dependent pathway.

Molecular modeling studies have revealed that serine 643 of PKC δ is situated at the apex of a ‘turn motif’ that is conserved in ABC kinases (Newton, 2003). Autophosphorylation of PKC isoforms at this serine/threonine residue in the ‘turn motif’ locks the enzyme in a catalytically competent conformation (Bornancin and Parker, 1996; Edwards et al., 1999). Our discovery that PKC δ co-immunoprecipitates with endogenous and recombinant Dexras1 from whole cell lysates suggests that Dexras1 may be interacting with PKC δ at, or near, its ‘turn motif’ to interfere with autophosphorylation of serine 643 and inhibit proper catalytic function. It is currently unclear, however, why Dexras1 specifically targets the δ isoform. One possible explanation may be that Dexras1 functions as a physiological regulator of PKC δ activity. In contrast to most PKC isoforms that require ‘priming’ by the upstream phosphoinositide-dependent kinase 1 (PDK1) for catalytic function, PKC δ has been shown to possess modest kinase activity in the absence of phosphorylation by PDK1 (Gschwendt, 1999; Stempka et al., 1997). This effect has been attributed to a glutamic acid residue situated five positions upstream of the PDK1 phosphorylation site (threonine 505) that may provide the negative charge required for structural integrity and catalytic function (Stempka et al., 1999). As PKC δ appears to be

MOL #19133

processed as a semi-active enzyme, Dexras1 may serve to suppress its basal kinase activity until the proper signal is relayed.

PKC δ is involved in many cellular processes such as growth, differentiation, and apoptosis (Kikkawa et al., 2002). PKC δ has been implicated to have a prominent role in oncogenesis. For example, regulation of PKC δ activity in rat primary tumors using a PKC δ inhibitory peptide was shown to decrease the metastatic potential of primary mammary tumor as determined by the development of secondary lung metastases (Kiley et al., 1999). In the MDA-MB-231 and MCF-7 human breast cancer cell lines, PKC δ has been shown to act as a pro-survival and pro-proliferative factor (De Servi et al., 2005; McCracken et al., 2003). Furthermore, PKC δ has been identified to be the predominant isoform expressed in MCF-7 cells, and anti-estrogen resistance of these cells is associated with the upregulation of PKC δ expression (Nabha et al., 2005; Shanmugam et al., 1999). Collectively, these studies suggest factors that act to impair PKC δ signaling may have a role in regulating oncogenesis. Dexras1 expression has been shown to inhibit clonogenic growth of MCF-7 and A549 cells (Vaidyanathan et al., 2004) which suggests that Dexras1 may have a regulatory role in oncogenesis by inhibiting PKC δ activity. Although protein kinase C has classically been thought to be pro-oncogenic by activating MAP kinase pathways (Hofmann, 2004), PKC isoforms might also regulate cellular proliferation by promoting adenylyl cyclase signaling, as studies support a positive role for cyclic AMP in cell growth and proliferation (Stork and Schmitt, 2002). Thus, the anti-proliferative effects of Dexras1 might be associated with its ability to inhibit PKC δ activity to negatively regulate two distinct oncogenic pathways: cyclic AMP signaling as we demonstrate in this report, and MAP kinase activation (Graham et al., 2002; Nguyen and Watts, 2005).

MOL #19133

In summary, the current study identifies a novel role for Dexras1 in cellular communication. We provide evidence that Dexras1 acts to negatively modulate AC2 signaling by interfering with PKC δ activity through an isoprenylation-dependent mechanism. These results are consistent with reports of a pertussis toxin-independent mechanism for Dexras1 in intact cells (Vaidyanathan et al., 2004). The role for Dexras1 in regulating PKC δ activity may provide novel therapeutic targets for drug therapy, as many physiological and pathophysiological processes are associated with altered PKC δ signaling.

ACKNOWLEDGEMENTS

The authors would like to thank Jamie L. Doran for critical reading of the manuscript. We would also like to thank Drs. Alex Toker, Peter Parker, and Shigeo Ohno for providing us with cDNA for the α , δ , and ϵ PKC isoforms. The Dexras1C277S mutant was a gift from Dr. Stephen Lanier and Govindan Vaidyanathan.

MOL #19133

REFERENCES

- Bol GF, Hulster A and Pfeuffer T (1997) Adenylyl cyclase type II is stimulated by PKC via C-terminal phosphorylation. *Biochim Biophys Acta* **1358**:307-13.
- Bornancin F and Parker PJ (1996) Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase Calpha. *Curr Biol* **6**:1114-23.
- Cismowski MJ, Ma C, Ribas C, Xie X, Spruyt M, Lizano JS, Lanier SM and Duzic E (2000) Activation of heterotrimeric G-protein signaling by a ras-related protein. Implications for signal integration. *J Biol Chem* **275**:23421-4.
- De Servi B, Hermani A, Medunjanin S and Mayer D (2005) Impact of PKCdelta on estrogen receptor localization and activity in breast cancer cells. *Oncogene* **24**:4946-55.
- Edwards AS, Faux MC, Scott JD and Newton AC (1999) Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. *J Biol Chem* **274**:6461-8.
- Fang M, Jaffrey SR, Sawa A, Ye K, Luo X and Snyder SH (2000) Dexas1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. *Neuron* **28**:183-93.

MOL #19133

Graham TE, Key TA, Kilpatrick K and Dorin RI (2001) Dexras1/AGS-1, a steroid hormone-induced guanosine triphosphate-binding protein, inhibits 3',5'-cyclic adenosine monophosphate-stimulated secretion in AtT-20 corticotroph cells. *Endocrinology* **142**:2631-40.

Graham TE, Prossnitz ER and Dorin RI (2002) Dexras1/AGS-1 inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases. *J Biol Chem* **277**:10876-82.

Graham TE, Qiao Z and Dorin RI (2004) Dexras1 inhibits adenylyl cyclase. *Biochem Biophys Res Commun* **316**:307-12.

Gschwendt M (1999) Protein kinase C delta. *Eur J Biochem* **259**:555-64.

Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G and Marks F (1994) Rottlerin, a novel protein kinase inhibitor. *Biochem Biophys Res Commun* **199**:93-8.

Hanoune J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. *Annu Rev Pharmacol Toxicol* **41**:145-74.

Hofmann J (2004) Protein kinase C isozymes as potential targets for anticancer therapy. *Curr Cancer Drug Targets* **4**:125-46.

MOL #19133

Jacobowitz O and Iyengar R (1994) Phorbol ester-induced stimulation and phosphorylation of adenylyl cyclase 2. *Proc Natl Acad Sci U S A* **91**:10630-4.

Kemppainen RJ and Behrend EN (1998) Dexamethasone rapidly induces a novel ras superfamily member-related gene in AtT-20 cells. *J Biol Chem* **273**:3129-31.

Kikkawa U, Matsuzaki H and Yamamoto T (2002) Protein kinase C delta (PKC delta): activation mechanisms and functions. *J Biochem (Tokyo)* **132**:831-9.

Kiley SC, Clark KJ, Goodnough M, Welch DR and Jaken S (1999) Protein kinase C delta involvement in mammary tumor cell metastasis. *Cancer Res* **59**:3230-8.

Li W, Zhang J, Bottaro DP and Pierce JH (1997) Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity. *J Biol Chem* **272**:24550-5.

McCracken MA, Miraglia LJ, McKay RA and Strobl JS (2003) Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. *Mol Cancer Ther* **2**:273-81.

Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K and Reddy KB (2005) Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. *Oncogene* **24**:3166-76.

MOL #19133

Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ and Teeter

MM (2001) Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. *Mol Pharmacol* **60**:373-81.

Newton AC (2001) Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. *Chem Rev* **101**:2353-64.

Newton AC (2003) Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. *Biochem J* **370**:361-71.

Nguyen CH and Watts VJ (2005) Dexas1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1. *Biochem Biophys Res Commun* **332**:913-920.

Shanmugam M, Krett NL, Maizels ET, Cutler RE, Jr., Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST and Hunzicker-Dunn M (1999) Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line. *Mol Cell Endocrinol* **148**:109-18.

Stempka L, Girod A, Muller HJ, Rincke G, Marks F, Gschwendt M and Bossemeyer D (1997) Phosphorylation of protein kinase Cdelta (PKCdelta) at threonine 505 is not a

MOL #19133

prerequisite for enzymatic activity. Expression of rat PKCdelta and an alanine 505

mutant in bacteria in a functional form. *J Biol Chem* **272**:6805-11.

Stempka L, Schnolzer M, Radke S, Rincke G, Marks F and Gschwendt M (1999) Requirements

of protein kinase cdelta for catalytic function. Role of glutamic acid 500 and

autophosphorylation on serine 643. *J Biol Chem* **274**:8886-92.

Stork PJ and Schmitt JM (2002) Crosstalk between cAMP and MAP kinase signaling in the

regulation of cell proliferation. *Trends Cell Biol* **12**:258-66.

Takesono A, Nowak MW, Cismowski M, Duzic E and Lanier SM (2002) Activator of G-protein

signaling 1 blocks GIRK channel activation by a G-protein-coupled receptor: apparent

disruption of receptor signaling complexes. *J Biol Chem* **277**:13827-30.

Thomas JM and Hoffman BB (1996) Isoform-specific sensitization of adenylyl cyclase activity

by prior activation of inhibitory receptors: role of beta gamma subunits in transducing

enhanced activity of the type VI isoform. *Mol Pharmacol* **49**:907-14.

Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD and Lanier SM (2004) The

Ras-related protein AGS1/RASD1 suppresses cell growth. *Oncogene* **23**:5858-63.

MOL #19133

Varga EV, Rubenzik MK, Stropova D, Sugiyama M, Grife V, Hraby VJ, Rice KC, Roeske WR

and Yamamura HI (2003) Converging protein kinase pathways mediate adenylyl cyclase

superactivation upon chronic delta-opioid agonist treatment. *J Pharmacol Exp Ther*

306:109-15.

Watts VJ and Neve KA (1996) Sensitization of endogenous and recombinant adenylyl cyclase

by activation of D2 dopamine receptors. *Mol Pharmacol* **50**:966-76.

Watts VJ and Neve KA (1997) Activation of type II adenylyl cyclase by D2 and D4 but not D3

dopamine receptors. *Mol Pharmacol* **52**:181-6.

Wetzker R and Bohmer FD (2003) Transactivation joins multiple tracks to the ERK/MAPK

cascade. *Nat Rev Mol Cell Biol* **4**:651-7.

MOL #19133

FOOTNOTES

This work was supported by The National Institutes of Health MH60397, DA13680, and a Purdue Research Foundation grant.

MOL #19133

FIGURE LEGENDS

Figure 1. Dexras1, $G\alpha_s$, $G\beta\gamma$, and PMA modulation of AC2. HEK-D_{2L} cells were co-transfected with AC2 in the absence or presence of Dexras1 using the dual expression vector, pBudCE4, as described in Materials and Methods. At 48 hr post-transfection cells were stimulated with (A) isoproterenol or (B) PMA in the absence and presence of 1 μ M quinpirole as indicated, for 15 min at 37°C in the presence of IBMX. Cyclic AMP accumulation was measured as described in Materials and Methods. The data are presented as mean \pm S.E.M. of 3 independent experiments performed in duplicate. Cyclic AMP accumulation is presented as pmol/well above vector-transfected cells. * $p < 0.05$ versus matched basal cyclic AMP accumulation. † $p < 0.05$ versus AC2 transfected cells for each stimulation condition (Repeated measures ANOVA with Bonferroni posttest).

Figure 2. PKC δ and PMA-dependent activation of AC2. (A) HEK-AC2 cells were stimulated with 100 nM PMA or 3 μ M isoproterenol in the absence and presence of 25 μ M rottlerin or 1 μ M bisindolylmaleimide for 15 min at 37°C in the presence of IBMX. Cyclic AMP accumulation was measured as described in Materials and Methods. The data are presented as mean \pm S.E.M. of 3 independent experiments performed in duplicate. Cyclic AMP accumulation is presented as fold above basal. Basal cyclic AMP accumulation values were: 6.3 \pm 0.7; + Rottlerin, 4.8 \pm 0.8; + Bis, 5.9 \pm 0.3 pmol/well. * $p < 0.05$ versus PMA-stimulated cyclic AMP accumulation alone (Repeated measures ANOVA with Bonferroni posttest). (B) HEK-D_{2L} cells were transiently transfected with AC2 in the absence and presence of PKC δ . At 48 hr post-transfection cells were stimulated with 100 nM PMA for 15 min at 37°C in the presence of

MOL #19133

IBMX. Cyclic AMP accumulation was subsequently measured as described in Materials and Methods. The data are presented as mean \pm S.E.M. of 3 independent experiments performed in duplicate. * $p < 0.05$ versus matched basal cyclic AMP accumulation. † $p < 0.05$ versus AC2 transfected cells for each stimulation condition (Repeated measures ANOVA with Bonferroni posttest).

Figure 3. Dexas1 expression and PKC autophosphorylation. The effect of Dexas1 on PKC autophosphorylation was examined in HEK-D_{2L} cells transiently transfected with PKC δ , PKC α , or PKC ϵ in the absence and presence of Dexas1. At 48 hr post-transfection cells were serum starved overnight. Cells were then lysed with ice-cold lysis buffer containing 1 % NP-40 and the detergent-soluble cell extracts were examined for autophosphorylation by immunoblot analysis using isoform-specific phospho-PKC antibodies as indicated. The blots were then stripped and reprobed with anti-PKC δ and/or anti-Dexas1 antibody as indicated. Immunoblots shown are representative of at least three independent experiments. (B) The phospho-PKC δ and PKC δ blots were examined for pixel intensity for the area under the curve generated for each individual band. The data are presented as phospho-/total PKC δ and have been normalized to values obtained from PKC δ transfection alone. The data are presented as mean \pm S.E.M of 4 independent experiments. * $p < 0.05$ compared to PKC δ transfection alone (One-sample t test).

Figure 4. Dexas1 and PKC kinase activity. HEK-D_{2L} cells were transiently transfected with PKC δ in the absence and presence of Dexas1. At 48 hr post-transfection cells were prepared for an *in vitro* PKC kinase assay as described in Materials and Methods. PKC specific activity was obtained by subtracting nonspecific activity from total catalytic activity. The data are expressed

MOL #19133

as mean \pm S.E.M. of 5 independent experiments performed in duplicate. * $p < 0.05$ versus untransfected control cells (Repeated measures ANOVA with Bonferroni posttest). Inset, immunoblot analysis of phospho-PKC δ and total PKC δ from the eluates following DEAE chromatography. Immunoblots shown are representative of two independent experiments.

Figure 5. Dexras1 and PKC δ interactions in intact cells. HEK-D_{2L} cells were co-transfected with PKC δ and either Dexras1 or pcDNA3 control. At 48 hr post-transfection cells were treated with 25 mM Dithiobis(succinimidyl)propionate at room temperature for 30 min. Cell lysates were then prepared for an immunoprecipitation assay as described in Materials and Methods. The lysate samples were incubated with beads alone, or in combination with anti-PKC δ antibody to immunoprecipitate PKC δ . Samples were then examined for Dexras1 immunoreactivity by immunoblot analysis as described in Materials and Methods. The blot was then stripped and reprobed with anti-PKC δ antibody. The input lane represents 5 μ l of cell lysate samples used for immunoprecipitation. Blot shown is representative of two independent co-immunoprecipitation experiments.

Figure 6. Dexras1 and PMA-dependent translocation of PKC δ . HEK-D_{2L} cells were transiently transfected with PKC δ in the absence and presence of Dexras1. At 48 hr post-transfection cells were serum starved overnight. Subsequently, cells were stimulated with 100 nM PMA for 30 min at 37°C. The reaction was terminated by removing the media and lysing the cells with ice-cold lysis buffer. Cells were then scraped from the plates and centrifuged at 100 000 \times g for 30 min at 4°C to separate the membrane and cytosolic fractions. PKC δ translocation was examined

MOL #19133

by immunoblot analysis using a phospho-specific PKC δ antibody as described in Materials and Methods. Shown is a representative immunoblot from three independent experiments.

Figure 7. Dexras1 isoprenylation and PKC δ autophosphorylation. The effect of FTI-277 was examined on Dexras1-mediated disruption of PKC δ autophosphorylation. (A) HEK-D_{2L} cells were transiently transfected with PKC δ in the absence and presence of Dexras1. At 5 hr post-transfection 10 μ M FTI-277 was added to the culture media. At 48 hr post-transfection cells were serum starved overnight, lysed with ice-cold lysis buffer containing 1 % NP-40, and the detergent-soluble cell extracts were examined for autophosphorylation by immunoblot analysis using a phospho-specific PKC δ antibody. Immunoblots shown are representative of three independent experiments. (B) The phospho-PKC δ and PKC δ blots were examined for pixel intensity for the area under the curve generated for each individual band. The data are presented as phospho-/total PKC δ and have been normalized to values obtained from matched PKC δ transfection alone. The data are presented as mean \pm S.E.M of 3 independent experiments. * $p < 0.05$ compared with PKC δ transfection alone (One-sample t test).

Figure 8. Cellular localization of wild-type and a CAAX box-deficient Dexras1 mutant (C277S). HEK-D_{2L} cells were transiently transfected with pcDNA3, Dexras1, or Dexras1C277S. At 48 hr post-transfection cells were scraped from the plates and centrifuged at 100 000 x g for 30 min at 4°C to separate the membrane and cytosolic fractions. Dexras1 expression was examined by immunoblot analysis using an anti-Dexras1 antibody as described in Materials and Methods. Shown is a representative blot from three independent experiments.

MOL #19133

Figure 9. Dexas1, Dexas1C277S, and PKC δ autophosphorylation. (A) HEK-D_{2L} cells were co-transfected with PKC δ and either wild-type Dexas1 or Dexas1C277S as indicated. At 48 hr post-transfection cells were serum starved overnight. Cells were then lysed with ice-cold lysis buffer containing 1 % NP-40 and the detergent-soluble cell extracts were examined for PKC δ autophosphorylation by immunoblot analysis as described in Materials and Methods. Immunoblot shown is representative of four independent experiments. (B) The phospho-PKC δ blots were examined for pixel intensity for the area under the curve generated for each individual band. The data have been normalized to values obtained for phospho-PKC δ immunoreactivity from PKC δ transfection alone. The data are presented as mean \pm S.E.M of 4 independent experiments. * $p < 0.05$ compared with PKC δ transfected conditions (One-sample t test). (C) HEK-D_{2L} cells were transiently transfected with pcDNA3, Dexas1, or Dexas1C277S and examined for Dexas1 expression by immunoblot analysis as described in Materials and Methods using an anti-Dexas1 antibody. Shown is a representative blot from 3 independent experiments.

Figure 10. Dexas1, Dexas1C277S, and AC2 activity. HEK-D_{2L} cells were co-transfected with PKC δ and either wild-type Dexas1 or Dexas1C277S as indicated. At 48 hr post-transfection cells were stimulated with 300 nM PMA for 15 min at 37°C in the presence of IBMX. Cyclic AMP accumulation was subsequently measured as described in Materials and Methods. The data are presented as mean \pm S.E.M. of 3 independent experiments performed in duplicate (Repeated measures ANOVA with Bonferroni posttest).

Figure 1




Figure 2





Figure 3




Figure 4




Figure 5




Figure 6





Figure 7

A



B




Figure 8






Figure 9



Transfection

PKCδ	-	-	+	+	+
Dexas1	-	+	-	+	-
C277S	-	-	-	-	+



C




Figure 10

